Abveris uses advanced immunization methods combined with B cell screening and hybridoma-based antibody discovery technologies to provide comprehensive gene to antibody discovery services. Berkeley Light's Beacon system captures deep phenotypic, functional, and genotypic information for thousands of single cells in parallel.

Abervis Single B Cell Antibody Discovery workflow was launched in 2019. The workflow combines DiversimAb hyperimmune mice and/or humanized mice with the Beacon system to provide antibody discovery solutions for the company's biopharmaceutical customers. In the last two years, Abervis has delivered panels of fully characterized antibody candidates for over 30 programs using the Berkeley Lights platform.

The addition of a second Beacon system will enable Abveris to increase throughput for campaigns requiring larger panels of candidate antibodies. It also improves the screening capacity for workflows that require complex, high-resolution screens. Based on increased capacity, the company is offering flexible business terms, including success-based structures.